Merck Serono in discovery deal to plump up immuno-oncology pipeline
This article was originally published in Scrip
Merck Serono, the biopharmaceutical arm of Merck of Germany, has signed an agreement with German biotech MorphoSys to discover and develop therapeutic antibodies against undisclosed immune checkpoints with the aim of developing new immune-oncology compounds.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.